Nomura Holdings Inc. cut its position in Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 24.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 194,600 shares of the biopharmaceutical company's stock after selling 63,900 shares during the period. Nomura Holdings Inc. owned approximately 0.36% of Emergent BioSolutions worth $1,860,000 at the end of the most recent quarter.
Other institutional investors have also recently modified their holdings of the company. Covestor Ltd boosted its position in Emergent BioSolutions by 5,458.5% in the fourth quarter. Covestor Ltd now owns 2,946 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 2,893 shares during the last quarter. Northern Trust Corp lifted its stake in Emergent BioSolutions by 2.6% during the 4th quarter. Northern Trust Corp now owns 145,889 shares of the biopharmaceutical company's stock valued at $1,395,000 after acquiring an additional 3,692 shares during the period. LPL Financial LLC boosted its holdings in shares of Emergent BioSolutions by 34.5% in the 4th quarter. LPL Financial LLC now owns 15,120 shares of the biopharmaceutical company's stock valued at $145,000 after acquiring an additional 3,875 shares during the last quarter. Federated Hermes Inc. increased its stake in shares of Emergent BioSolutions by 2.2% in the fourth quarter. Federated Hermes Inc. now owns 277,810 shares of the biopharmaceutical company's stock worth $2,656,000 after acquiring an additional 6,058 shares during the period. Finally, SBI Securities Co. Ltd. purchased a new position in shares of Emergent BioSolutions during the fourth quarter worth $63,000. 78.40% of the stock is currently owned by hedge funds and other institutional investors.
Emergent BioSolutions Price Performance
EBS traded up $0.04 during trading on Thursday, hitting $6.47. The company's stock had a trading volume of 439,632 shares, compared to its average volume of 1,855,723. The firm has a market capitalization of $351.18 million, a price-to-earnings ratio of -1.58 and a beta of 2.09. Emergent BioSolutions Inc. has a twelve month low of $4.02 and a twelve month high of $15.10. The business's fifty day simple moving average is $5.21 and its 200 day simple moving average is $7.75. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30.
Emergent BioSolutions (NYSE:EBS - Get Free Report) last announced its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.49 by $0.22. The business had revenue of $222.20 million for the quarter, compared to analyst estimates of $218.50 million. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. On average, equities research analysts forecast that Emergent BioSolutions Inc. will post -0.63 EPS for the current fiscal year.
Emergent BioSolutions declared that its board has approved a stock buyback plan on Monday, March 31st that permits the company to repurchase $50.00 million in shares. This repurchase authorization permits the biopharmaceutical company to purchase up to 19% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company's board believes its shares are undervalued.
Analysts Set New Price Targets
Several equities research analysts have commented on EBS shares. Wall Street Zen lowered shares of Emergent BioSolutions from a "buy" rating to a "hold" rating in a report on Wednesday, March 5th. HC Wainwright reissued a "buy" rating and set a $15.00 price target on shares of Emergent BioSolutions in a report on Tuesday, April 1st.
Read Our Latest Stock Report on Emergent BioSolutions
Insider Buying and Selling
In other news, Director Neal Franklin Fowler sold 35,000 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $5.83, for a total value of $204,050.00. Following the transaction, the director now owns 101,100 shares in the company, valued at $589,413. This trade represents a 25.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 3.20% of the stock is currently owned by insiders.
About Emergent BioSolutions
(
Free Report)
Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.
See Also
Before you consider Emergent BioSolutions, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Emergent BioSolutions wasn't on the list.
While Emergent BioSolutions currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
